January 17, 2023; San Diego, California – Excellos, the California-based, full-service CDMO, has today announced the launch of ‘Excellos 360’,... View Article
In a recent publication [1], a collaborative research group based in La Jolla, CA cite using Excellos sourced T cells... View Article
Scientists at the University of Florida College of Medicine report that natural variability in donor stem cells can have a... View Article
CHARLOTTE, N.C. and SAN DIEGO, Oct. 26, 2022 /PRNewswire/ — Barings, one of the world’s largest diversified real estate investment managers, along with Phase... View Article
Researchers at the La Jolla Institute for Immunology cite using Excellos sourced healthy donor starting material to carry out single-cell... View Article
A case of immune T-cell identity theft gave German scientists the vital clue they needed to understand a key mechanism... View Article
Scientists at Scripps Research Center in La Jolla are working to streamline monoclonal antibody vaccine development by devising more efficient... View Article
Researchers at UCSD and Memorial Sloan Kettering Cancer Center used Excellos healthy donor starting material to carry out a fascinating... View Article
NK cell therapy holds the promise of new therapeutics for underserved cancer indications. A recent publication in Nature Communications uses... View Article
A new Allogeneic CAR-T study has shown CAR-T cells derived from healthy donors to be superior at fighting cancer compared... View Article